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ABSTRACT 
The solubility and dissolution rate of simvastatin, a drug used for the treatment of hyperlipidaemia. Simvastatin is a 
selective competitive inhibitor of HMG Co A reductase. However its absolute bioavailability is 5%. To increase the 
solubility of drug solid dispersion was prepared. Solid dispersion preliminary solubility analysis was carried out for the 
selection of the carrier and solid dispersion was prepared with Hydroxy Propyl Methyl Cellulose (HPMC) and Methyl 
Cellulose (MC). These solid dispersions were analyzed for the solubility and in-vitro dissolution profile solid 
dispersion of drug with polymer has shown enhanced solubility with improved dissolution rate. Further FTIR, X-Ray 
studies were carried out. Solid dispersion prepared with polymer in 1:5 ratios shows the presence of amorphous form 
confirmed by the characterization study. The study also shows that dissolution rate of simvastatin can be enhanced to 
considerable extent by solid dispersion technique with Polymer. 
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INTRODUCTION 
In recent years, many drug delivery systems like soild 
dispersion
1
, liposome
2, 3
, nanoemulsion etc used in 
order to model the kinetics release, improve the 
absorption and increase stability drugs. From this arose 
the main difficulties with regard to the development 
and the therapeutic activity of many drugs, which 
results in large part to the low aqueous solubility of 
drugs
1
. 
Thus, some techniques can be used to increase the 
solubility of drugs, independent of their chemical 
structure and dimension Molecular space
4, 5
. Since 
solid dispersion increases the solubility of the drugs, it 
has become one of the most active areas of research in 
the pharmaceutical field. This technique produces a 
significant reduction in particle size drug with 
increased uniformity and surface contact, allowing 
dissolution and faster absorption
6
. 
The production of solid dispersions (SDs) is one of the 
acknowledged methods and used to enhance the 
aqueous solubility, thereby increasing the oral 
bioavailability and dissolution rate of drugs with 
aqueous low solubility
1, 7
. 
Because of the toxicity and environmental problems 
associated with the use of organic solvents, the use the 
fusion method represents an advantageous means in 
Preparation of SD when the drug is stable Thermal. 
However, its use is inappropriate when there 
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polymorphism due to transition that may occur during 
fusion between the polymorphic forms 
8, 9
.  
Simvastatin (BCS II drug) is a white crystalline 
powder form and (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a–
hexahydro–3,7–dimethyl–8-[2-[(2R,4R)-tetrahydro–4–
hydroxy–6–oxo–2H-pyran–2yl]ethyl]-1–naphthalenyl 
ester. After oral ingestion, SMS, an inactive lactone, is 
hydrolyzed to the corresponding β-hydroxyacid form. 
This is a principal metabolite and an inhibitor of 3-
hydroxy-3-methylglutaryl-coenzyme-A (HMG Co-A) 
reductase, the enzyme that catalyses an early and rate-
limiting step in the biosynthesis of cholesterol. It is a 
Hypolipidemic drug having a potent inhibitor of HMG-
CoA reductase inhibitor and used to treat the 
Hypercholestremia, Dyslipidemia and coronary heart 
diseases.
10, 11, 12
 Hdroxy Propyl Methyl Cellulose  
(HPMC) is a   2-hydroxy propyl methyl ether  and 
soluble in ethanol, methanol and propanol.  Methyl 
Cellulose (MC) is a Methyl Ether of Cellulose and 
soluble in water, glacial acetic acid and both these 
polymers used as a soluility enhancer and improving 
the dissolution rate of water insoluble drug. 
MATERIAL AND METHODS 
Materials 
The Simvastatin gift sample was received from Dr. 
Reddys’ Pharmaceuticals’ Ltd. Hyderabad. The 
Hydroxy propyl methyl cellulose (HPMC) and Methyl 
cellulose (MC) polymers were gifted from Signet 
Chemicals Pvt. Ltd and Loba Chem Pvt. Ltd Mumbai. 
The other chemicals are ethanol, methanol, magnesium 
state, talc, lactose; disodium hydrogen orthophosphate 
and potassium dihydrogen orthophosphate were 
purchased from Loba Chemicals Mumbai, India. 
Methods
9
 
Physiochemical Characterisation of Pure Drug
 
 
The drug sample (Simvastatin) was analysed by 
different means such as color, odor and texture in order 
to prove the authenticity of the sample.  
Determine the Solubility of Pure Drug by using UV 
Spectroscopic Method 
A. Determination Absorption Maxima of the 
Drug (λ max) 
A UV absorption maxima of the drug was determined 
by scanning (10μg/ml) solution of drug in methanol 
between 200-400nm.  
B. Preparation of Calibration Curve in 
phosphate buffer (pH 6.8)   
10mg of Simvastatin was dissolved in small amount of 
methanol (used as co solvent) and diluted to 100ml of 
phosphate buffer pH6.8. 50ml of this solution was 
taken and diluted to 100ml with phosphate buffer 
pH6.8 to prepare a stock solution of 250μg/ml as a 
stock solution. From this stock solution, aliquots of 2, 
4, 6, 8, 10 and 12were transferred to 10ml volumetric 
flask and volume was made up to 10ml with phosphate 
buffer. The absorbance of these solutions was 
measured at 239.5nm using phosphate buffer as blank. 
 
C. Preparation of Calibration Curve in 
Methanol 
10mg of Simvastatin was dissolved in 100ml 
methanol; 50ml of this solution was taken and diluted 
to 100ml again with methanol to prepare a stock 
solution of 250μg/ml as a stock solution. From this 
stock solution, aliquots of 2, 4, 6, 8, 10 and 12 were 
transferred to 10ml volumetric flask and volume was 
made up to 10ml with methanol. The absorbance of 
these solutions was measured at 238nm using methanol 
as blank. 
Preparation of solid dispersions of simvastatin 
Melt Method
7
 
The fusion method is sometimes referred to as the melt 
method. The polymer HPMC was melted at 60°C and 
then the drug was added, mixed well and cooled in an 
ice bath to obtain a solid mass. The solidified mass was 
crushed and passed through a sieve No. 60. The 
resulting solid dispersion was stored in a desiccator 
until further evalution.Same procedure carry out with 
methyl cellulose. 
Characterization of solid dispersions
9, 13, 14
 
The prepared physical mixtures and solid dispersions 
were evaluated for percentage yield, drug content, 
solubility studies, Fourier transform infrared (FTIR), 
Differential scanning calorimetry (DSC), X-ray 
diffraction (XRD), in vitro drug release and dissolution 
efficiency. 
Percentage of Practical Yield 
The percent yield of Simvastatin solid dispersions was 
determined by using the following formula: 
[PY (%) = [Practical Mass (Solid dispersion)/ 
Theoretical Mass (Drug+ Carrier) ×100] eq 1 
 Determination of Drug Content 
Solid dispersions equivalent to 10mg of Simvastatin 
were weighed accurately and dissolved in 10ml of 
methanol. The solution was filtered, diluted suitably 
and drug content was analyzed at 238 nm by UV 
Spectrophotometer. 
In vitro Drug Release 
Accurately weighed preparations equivalent to 10 mg 
of Simvastatin were added to 900 ml of dissolution 
media (6.8 phosphate buffer) contained in USP 
dissolution apparatus II and stirred at a speed of 50 
rpm at 37±0.5˚C. 5ml aliquots were withdrawn at 10, 
20, 30, 40, 50 60 minute and replaced by 5 ml of fresh 
dissolution media (37˚C). The collected samples were 
analyzed after suitable dilution at 239.5 nm using UV-
visible spectrophotometer against the blank. The 
dissolution of pure Simvastatin was done similarly.
 
Saturation solubility studies  
Saturation solubility was determined by adding excess 
amounts of solid dispersions to water and bio relevant 
media at 37 ± 0.5°C, respectively. The solutions were 
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equilibrated under continuous agitation for 24 h and 
filtered through Whatman filter paper to obtain a clear 
solution. The absorbance of the samples was measured 
by UV spectrophotometer (WFZ 800-D2, Beijing 
Second Telescope Factory) at 238 nm and the 
concentrations in µg/ml were determined. Each sample 
was determined in triplicate.   
 Powder X-Ray Diffraction (XRD) Analysis 
The crystallinity of samples was investigated by XRPD 
using Bruker diffractometer (WI 1140, Japan) and Cu-
Kα radiation. The diffractograms were run at 2.5 °C 
min-1 and chart speed of 2°/2 cm per 2θ angle.   
 Fourier Transform Infrared (FTIR) Spectroscopy
 
Simvastatin and solid dispersions were further 
characterized by FT-IR. Samples prepared in KBr discs 
were subjected to FTIR recording on FTIR- 8400S, CE 
(Shimadzu, Japan) instrument (SEM). Data was 
collected over a spectral range of 4000 to 400 cm
-1
.    
After the characterisation of the prepared solid 
dispersions on the basis of dissolution studies and 
optimise the formulation from the drug release studies 
and select the highest drug:polymer ratio  which shows 
maximum release in the phosphate buffer pH6.8. and 
its  calculative parameters as shown respectively.
 
Stability studies 
 
Accelerated stability studies were performed on 
prepared solid dispersion in amber coloured screw 
capped bottles and was checked as per ICH guidelines 
at 40±2
o
C and 75±5% RH up to one month. The solid 
dispersions were kept in stability chamber. Samples 
were removed at regular intervals as initial, 7 days, 14 
days, 21days and 30 days and were analysed for 
physical characterization, content uniformity and in 
vitro dissolution studies. The similarity factor (f2) was 
used as a basis to compare dissolution profiles. The 
dissolution profiles. The dissolution profiles are 
considered to be similar when f2 is between 50 and 
100. The dissolution profiles of C1 formulation before 
and after stability testing were compared using a 
similarity factor (f2) which is a calculated from the 
following formula. 
f2 =50 log {[1+ 
 
 
       t – Tt)
2
]
-0.5 
100}                       
................eq 2 
Where, n is the dissolution time and Rj  and Tj are the 
reference and test dissolution values at time t. (Morre 
Flamer equation).  
A model independent method for comparison of two 
dissolution profiles is based upon similarity factor f2 
and difference factor f1.similarity factor as discussed 
above, the equation of difference factor discussed 
below. 
f2 =    
 
   t – Tt) /  
 
   t                                                                 
.................eq  3 
RESULT AND DISCUSSION 
Physical Appearance  
Physical appearance of drug was studied by its various 
organoleptic properties.  The sample of simvastatin 
was found to be white, non hygroscopic, crystalline 
solid powder. The melting point of simvastatin was 
found to be in the range of 135 -140
0
C by Capillary 
method. 
Absorption Maxima  
Absorption maxima (λ max) of simvastatin were 
observed in different solvents. 
 
Table 1: Absorption maxima (λmax) of the Simvastatin  
 
 
 
 
Solubility 
The solubility studies of Simvastatin were determined in different solvents. 
Table 2 Solubility of Simvastatin in different solvents 
Solvent Solubility 
Phosphate buffer 4.036±0.549 
Methanol 2.516±0.166 
Data Expressed as mean ± S.D (n=3) 
 
Standard curves  
The standard curve of simvastatin was found to be linear 
at 237nm in phosphate buffer (pH6.8) in the 
concentration range of 2-12(µg/ml), which obeys 
Lambart Beer Law. The absorbance at different 
concentrations is shown in tables and graph is 
represented in figure respectively. 
 
Solvent (λmax)nm 
Phosphate buffer 239nm 
Methanol 238nm 
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Figure 1: Standard Curve of Simvastatin in 
Phosphate Buffer (pH6.8) 
 
 
Figure 2: Standard Curve of Simvastatin in 
Methanol
 Percent yield and drug content  
The percent yield and drug content of pure drug and different solid dispersions which are prepared with polymers were 
determined. The % yields decreased at the higher concentrations due to the difficulty in sieving at higher polymer and 
surfactants concentration.  
                                Table 3: Percent yield or drug content of solid dispersions Sim/HPMC 
 
 
 
 
                                          
Data Expressed as mean ± S.D (n=3) 
Table 4: Percent yield or drug content of solid dispersions Sim/MC 
 
 
 
 
 
 
Data Expressed as mean ± S.D (n=3) 
Table 5: Percentage yield and drug content of solid dispersion Simvastatin MC: HPMC 
 
   
                      
 
 
Data Expressed as mean ± S.D (n=3) 
Solubility studies 
Solubility data of pure drug and different solid dispersions as shown in given Table 6 to 8 respectively. Solubility of 
drug increased with increased in the ratio of polymer. 
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Concentration(µg/ml) 
Absorbance vs concentration 
Formulation Code Percentage yield Drug content 
SIH1:1 95.52±0.804 84.42±0.020 
SIH1:3 94.81±0.635  91.73±0.006 
SIH1:5 90.27±0.245 95.96±0.009 
Formulation Code Percentage yield Drug content 
SM1:1 90.14±0.759 77.69±0.018 
SM1:3 89.63±0.514 87.88±0.007 
SM1:5 89.26±0.865 84.23±0.016 
Formulation Code Percentage yield Drug content 
SHM1:1 92.29±0.935 85.76±0.015 
SHM1:3 91.99±0.404 89.61±0.016 
SHM1:5 92.54±0.402 92.11±0.007 
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Table 6: Solubility of Pure Drug Simvastatin and HPMC 
 
                                
 
 
 
 
 
Table 7: Solubility of Pure Drug Simvastatin and MC 
 
 
 
                                        
 
 
 
Data Expressed as mean ± S.D (n=3) 
                   
Table 8: Solubility of Pure Drug Simvastatin and HPMC: MC 
 
 
 
 
 
 
 
Data Expressed as mean ± S.D (n=3) 
 
In Vitro Dissolution studies  
The In vitro release of pure drug and different solid dispersions were determined and plotted the graph between % drug 
released vs time.  
 
Figure 3: In vitro dissolution profile of %drug released vs time pure drug and Solid dispersions (Sim/HPMC) 
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Time 
PURE DRUG 
SIH1:1 
SIH 1:3 
SIH1:5 
Formulation Code Solubility 
Pure drug 4.036±0.549 
SIH 1 6.156±0.645 
SIH2 7.043±0.422 
SIH3 8.273±0.159 
Formulation Code Solubility 
Pure drug 4.036±0.549 
SM1 5.356±0.285 
SM2 6.066±0.351 
SM3 7.676±0.442 
Formulation Code Solubility 
Pure drug 4.036±0.549 
SHM1 9.516±0.232 
SHM2 11.186±0.178 
SHM3 12.516±0.232 
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Figure 4: In vitro dissolution profile of %drug released vs time pure drug and Solid    dispersions (Sim/MC) 
 
X-ray diffraction studies 
The X-ray diffraction studies of pure simvastatin and 
optimized solid dispersions of both polymers HPMC 
and Methyl Cellulose. The characteristics diffraction 
peaks of simvastatin present peaks at (2θ) 9.63o, 11.24o, 
15.90o, 16.889o, 17.56o, 18.04o, 19.74o, 22.84o, 
28.68o, 33.51o, 35.17o, and 38.73o indicate the pr 
crystalline nature of the drug. Peaks of optimized solid 
dispersion shows the reduction in peak height area 
which indicates the reduction in the crystallinity nature 
of the simvastatin as some of the drug converted into the 
amorphous form in the solid dispersions. 
 
                                            
Figure 5: X-ray diffraction of Simvastatin 
                
Figure 6: X-ray diffraction of Simvastatin with HPMC/MC 
Infrared spectroscopy  
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The spectrum of solid dispersions exhibited significant 
decrease in intensity of O-H stretching vibrations which 
may be due to intermolecular hydrogen bonding. The 
spectra peaks of drug were almost unchanged in the 
optimized solid dispersions which indicate that the 
overall symmetry of molecule was not affected 
 
                                                    
Figure 7: IR Spectra of Simvastatin 
 
 
Figure 8: IR Spectra of optimized solid dispersion with (HPMC/MC) 
 
Optimized formulation  
On the basis of dissolution data optimized formulation is detected and formula was prepared which was shown below 
the table. 
Table 9: Dissolution efficiency and yield of optimized formulations 
Optimized formulation %DE60 % Yield 
100:500 65.44 90.27 
100:500 53.41 89.26 
100:250:250 60.90 92.54 
 
 
Table 10: Evaluation parameters of optimized solid dispersion (HPMC) after stability 
RC SAIF PU, Chandigarh 
  Komal Jal-1.sp - 4/7/2015 - HPMC/MC/1:5  
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Figure 9: Drug Release Data of Before and After Storage (Sim/HPMC) 
 
Table 11: Evaluation parameters of optimized solid dispersion (MC) after stability 
 
 
Figure 10: Drug Release Data of Before and After Storage (Sim/MC) 
Table 12: Evaluation parameters of optimized solid dispersion (HPMC: MC) after stability 
Time period (in days) 0 7 14 21 30 
Color appearance No change in 
color 
No change in 
color 
No change in 
color 
 No change in 
color 
No change in 
color 
Drug release - - - - 93.23 
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Before sability After stability 
Time period (in 
days) 
0 7 14 21 30 
Color appearance No change in 
color 
No change in 
color 
No change in 
color 
 No change in 
color 
No change in 
color 
Drug release - - - - 95.47 
Time period (in days) 0 7 14 21 30 
Color appearance No change in 
color 
No change in 
color 
No change in 
color 
 No change in 
color 
No change in 
color 
Drug release - - - - 91.17 
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Figure 11: Drug Release Data of Before and After Storage (Sim/MC: HPMC) 
 
From all above the dissolution data, it shows that there 
will no change from the above dissolution data and 
graph, that there is no change to be observed in prepared 
optimized solid dispersion. The value to be calculated 
from the equation and drug release value is 93.23 that is 
become met similar with the standard so that the 
optimized solid dispersion was stable after the stability 
studies.
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